SHANGHAI, China I November 8, 2024 I Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, showcased the “Preclinical Development of 7MW4811, an Mtoxin™ (MF6)-based Antibody-drug Conjugate for the Treatment of Solid Tumors” as a poster presentation at the 15th World ADC San Diego, held from Nov. 4 to 7, 2024. The post revealed compelling data from the studies on the efficacy of 7MW4811 in treating solid tumors.
7MW4811 is developed with Mabwell’s next-generation ADC technology (IDDC™) platform, and has demonstrated encouraging anti-tumor effects across a range of solid tumors, including lung, colorectal, pancreatic and gastric cancers. Notably, it has shown promising therapeutic potentials in gastrointestinal tumors.
IDDC™ is a clinically validated site-specific conjugation technology that has been instrumental in the development of ADCs with good homogeneity, efficacy, and safety profiles. Coupled with the novel payload Mtoxin™ (MF6), these ADCs have been furthered optimized, exhibiting enhanced pharmacodynamics, bystander killing efficacy, and anti-multidrug resistance capabilities.
About Mabwell
Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with the entire value chain of the pharmaceutical industry. We provide more effective and accessible therapy and innovative medicines to fulfill global medical needs. Since 2017, an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation was established. Mabwell has 15 pipeline products in different stages based on a world-class and state-of-the-art R&D engine, including 11 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of oncology, immunology, bone disorders, ophthalmology, hematology and infectious diseases, etc. Of these, 3 products have been approved and commercialized, 1 product has been filed for MA, 3 products are in pivotal trials. We have also undertaken 1 national major scientific and technological special project for “Significant New Drugs Development”, 2 projects for National Key R&D Programmes, and multiple provincial and municipal science and technological innovation projects. Mabwell’s Taizhou factory possesses robust in-house manufacturing capability compliant with international GMP standards regulated by the NMPA, FDA and EMA, and has passed the EU QP Audit. The large-scale manufacturing base in Shanghai and the ADC commercialized manufacturing base in Taizhou are under construction. Our mission is “Explore Life, Benefit Health” and our vision is “Innovation, from ideas to reality”. For more information, please visit www.mabwell.com/en.
SOURCE: Mabwell
Post Views: 1,511
SHANGHAI, China I November 8, 2024 I Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, showcased the “Preclinical Development of 7MW4811, an Mtoxin™ (MF6)-based Antibody-drug Conjugate for the Treatment of Solid Tumors” as a poster presentation at the 15th World ADC San Diego, held from Nov. 4 to 7, 2024. The post revealed compelling data from the studies on the efficacy of 7MW4811 in treating solid tumors.
7MW4811 is developed with Mabwell’s next-generation ADC technology (IDDC™) platform, and has demonstrated encouraging anti-tumor effects across a range of solid tumors, including lung, colorectal, pancreatic and gastric cancers. Notably, it has shown promising therapeutic potentials in gastrointestinal tumors.
IDDC™ is a clinically validated site-specific conjugation technology that has been instrumental in the development of ADCs with good homogeneity, efficacy, and safety profiles. Coupled with the novel payload Mtoxin™ (MF6), these ADCs have been furthered optimized, exhibiting enhanced pharmacodynamics, bystander killing efficacy, and anti-multidrug resistance capabilities.
About Mabwell
Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with the entire value chain of the pharmaceutical industry. We provide more effective and accessible therapy and innovative medicines to fulfill global medical needs. Since 2017, an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation was established. Mabwell has 15 pipeline products in different stages based on a world-class and state-of-the-art R&D engine, including 11 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of oncology, immunology, bone disorders, ophthalmology, hematology and infectious diseases, etc. Of these, 3 products have been approved and commercialized, 1 product has been filed for MA, 3 products are in pivotal trials. We have also undertaken 1 national major scientific and technological special project for “Significant New Drugs Development”, 2 projects for National Key R&D Programmes, and multiple provincial and municipal science and technological innovation projects. Mabwell’s Taizhou factory possesses robust in-house manufacturing capability compliant with international GMP standards regulated by the NMPA, FDA and EMA, and has passed the EU QP Audit. The large-scale manufacturing base in Shanghai and the ADC commercialized manufacturing base in Taizhou are under construction. Our mission is “Explore Life, Benefit Health” and our vision is “Innovation, from ideas to reality”. For more information, please visit www.mabwell.com/en.
SOURCE: Mabwell
Post Views: 1,511
